This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Jul 2011

Leukocare and Sanofi Pasteur Jointly Work on Vaccine Stabilisation

Sanofi Pasteur and Leukocare will cooperate to evaluate Leukocare’s Stabilizing and Protecting Solutions platform for improving the shelf-life of certain vaccine formulations.

Leukocare, a specialist company for protein stabilisation and biological surface coating, has inked a co-operation deal with Sanofi Pasteur, the vaccines division of Sanofi. Under the agreement, Sanofi Pasteur will explore Leukocare’s Stabilising and Protecting Solutions (SPS) platform technology to enhance the shelf-life of selected vaccine formulations.


Leukocare’s SPS technology is employed in the biopharmaceutical, medical device and diagnostics industries to enhance the shelf-life of proteins and to enable terminal sterilisation by irradiation or ethylene oxide.


Terminal sterilisation allows for a significant reduction in production costs by avoiding complex aseptic production and at the same time, improves product safety, as most sources of erro

Related News